NASD · Healthcare · Biotechnology · Israel
Entera Bio Ltd is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Entera Bio is a clinical-stage company developing oral tablets containing peptides and protein replacement therapies for chronic medical conditions. Its pipeline includes candidates for parathyroid hormone, glucagon-like peptide, and related treatments, using the company's N-Tab® platform to stabilize peptides in the gastrointestinal tract and enhance absorption into the bloodstream.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Entera Bio Ltd stock.
Not valued: We cannot value this company yet.
134 more in this industry show a wider margin of safety.
We do not publish a verdict on ENTX yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-30 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.